Selective copper(II) removal using molecularly imprinted alginate-metformin hydrogel beads: Mechanistic insights from isotherms, DFT and molecular docking
Abstract
A copper(II)-imprinted hydrogel (Cu-Imp) was developed using sodium alginate and metformin hydrochloride to fabricate structurally selective polymeric beads for efficient Cu(II) removal from aqueous solutions. The imprinting strategy leveraged the coordination chemistry of Cu(II) with nitrogen donors from metformin and carboxylate groups from alginate to construct high-fidelity recognition sites. Experimental characterization confirmed morphological refinement (SEM), selective Cu uptake (EDX), and functional group interaction (FTIR). The Cu-Imp beads achieved a maximum adsorption capacity of 50.21 mg/g and a Cu(II) removal efficiency of 96.3 % at an initial concentration of 10 mg/L. Isotherm modeling indicated strong agreement with the Redlich-Peterson (R2 = 0.948) and Koble-Corrigan (R2 = 0.947) models, suggesting heterogeneous monolayer-multilayer adsorption. Kinetic analysis revealed pseudo-second-order and Elovich models as the best fit (R2 = 0.986-0.997), confirming chemisorption with a rate-limiting electron-sharing mechanism. Molecular docking revealed favorable Cu-OH binding orientations, while DFT calculations validated strong Cu-O/N coordination at pH 5.4, with an adsorption energy of -60.34 kcal/mol and a HOMO-LUMO gap of 0.087 eV, indicating high electronic reactivity. The material demonstrated excellent regeneration capacity, maintaining ~26.8 mg/g performance over five cycles. Together, these findings confirm the success of the molecular imprinting strategy and…
How strong is the evidence?
Evidence Hub reads this as a simulation / modelling, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.